1. Home
  2. LDOS vs UTHR Comparison

LDOS vs UTHR Comparison

Compare LDOS & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Leidos Holdings Inc.

LDOS

Leidos Holdings Inc.

HOLD

Current Price

$150.06

Market Cap

22.5B

Sector

Technology

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$571.85

Market Cap

25.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LDOS
UTHR
Founded
1969
1996
Country
United States
United States
Employees
47000
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.5B
25.1B
IPO Year
2005
1999

Fundamental Metrics

Financial Performance
Metric
LDOS
UTHR
Price
$150.06
$571.85
Analyst Decision
Buy
Buy
Analyst Count
13
14
Target Price
$203.15
$567.57
AVG Volume (30 Days)
688.1K
387.7K
Earning Date
05-05-2026
05-06-2026
Dividend Yield
1.18%
N/A
EPS Growth
20.82
13.07
EPS
11.14
27.86
Revenue
$17,174,000,000.00
$1,483,300,000.00
Revenue This Year
$6.50
$6.39
Revenue Next Year
$4.40
$14.18
P/E Ratio
$13.40
$20.56
Revenue Growth
3.07
2.38
52 Week Low
$139.69
$272.18
52 Week High
$205.77
$607.89

Technical Indicators

Market Signals
Indicator
LDOS
UTHR
Relative Strength Index (RSI) 41.39 54.70
Support Level N/A $560.16
Resistance Level $161.39 $593.65
Average True Range (ATR) 3.60 12.17
MACD 0.17 -3.01
Stochastic Oscillator 39.52 30.53

Price Performance

Historical Comparison
LDOS
UTHR

About LDOS Leidos Holdings Inc.

Leidos Holdings Inc is a technology, engineering, and science company that provides services and solutions in the defense, intelligence, civil, and health management, both domestically and internationally. The customers of the company includes the U.S. Department of Defense ("DoD"), the U.S. Intelligence Community, the U.S. Department of Homeland Security ("DHS"), the Federal Aviation Administration ("FAA"), the Department of Veterans Affairs ("VA"), and many other U.S. civilian, state and local government agencies, etc. The company is engaged in four reportable segments; National Security & Digital, Health & Civil, Commercial & International and Defense Systems. It provides a wide array of scientific, engineering and technical services and solutions across these reportable segments.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

Share on Social Networks: